The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Open accessAbstract
BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation. METHODS: In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety. RESULTS: Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). CONCLUSIONS: Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan was associated with a 13.6% risk of interstitial lung disease (ILD)/pneumonitis, fatal in 2.2% of cases, which needed appropriate and rapid diagnosis and treatment.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan (DS-8201), an ADC composed of trastuzumab, a cleavable tetrapeptide-based linker and a cytotoxic topoisomerase I inhibitor, demonstrated a response rate of 60.6% (95% CI 53.4-68.0) and an unprecedented median PFS of 16.4 months (95% CI 12.7—not reached) in a phase II study of heavily pretreated patients (median six lines, range 2-27 lines, including trastuzumab and T-DM1).64”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+ · Cited by 16,760
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Self-citationPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citationOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,205
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., van de Vijver, M. J., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. O. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,190
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobágyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,163
Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009) · Clinical Medicine & Research · doi:10.3121/cmr.2009.825 · Cited by 1,023
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- 10.3121/cmr.2008.825 · DOI
- Modi S Tsurutani J Takahashi S et al. Safety and efficacy results from a phase 1 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2 expressing metastatic breast cancers. Presented at the 2017 San Antonio Breast Cancer Symposium San Antonio TX December 5–9 2017.
Cited by
Sorted by citations
Items 501–600 of 1,000
Shin, C., Kim, S. S., & Jo, Y. H. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.08.005 · Cited by 27
Self-citationSode, M., Thagaard, J., Eriksen, J. O., & Lænkholm, A. (2023) · Histopathology · doi:10.1111/his.14877 · Cited by 27
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Popović, M., Silovski, T., Križić, M., & Plavetić, N. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098206 · Cited by 29
Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment
Marta, G. N., Molinelli, C., Debien, V., Martins-Branco, D. A., Aftimos, P. G., de Azambuja, E., & Awada, A. H. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231183679 · Cited by 27
Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions
Yang, T.-L., Li, W., Huang, T., & Zhou, J. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511903 · Cited by 27
History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer
Ariga, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103391 · Cited by 26
Curigliano, G., Dent, R. A., Earle, H., Modi, S., Tarantino, P., Viale, G., & Tolaney, S. M. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102989 · Cited by 26
Self-citationBrasó‐Maristany, F., Ferrero-Cafiero, J. M., Falato, C., Martínez‐Sáez, O., Cejalvo, J. M., Vila, M. M., Tolosa, P., Salvador-Bofill, F. J., Cruz, J., González‐Farré, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50056-y · Cited by 26
Sakai, H., Tsurutani, J., Ozaki, Y., Ishiguro, H., Nozawa, K., Yamanaka, T., Aogi, K., Matsumoto, K., Iwasa, T., Tokiwa, M., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.001 · Cited by 26
Self-citationKhatri, V. M., Mestres-Villanueva, M. A., Yarlagadda, S., Doniparthi, A., Smith, D. B., Nakashima, J. Y., Bryant, J. M., Zhao, D., Upadhyay, R., Mills, M. N., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00711-w · Cited by 26
Pancreatic Cancer: Pathogenesis and Clinical Studies
Zhou, K., Liu, Y., Tang, C., & Zhu, H. (2025) · MedComm · doi:10.1002/mco2.70162 · Cited by 28
Genomic Alteration in Metastatic Breast Cancer and Its Treatment
Li, A., Schleicher, S. M., André, F., & Mitri, Z. I. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280463 · Cited by 26
Perdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy
Jiang, M., Li, W., Zhu, C., Li, X., Zhang, J., Luo, Z., Qin, B., Du, Y., Luo, L., & You, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.031 · Cited by 26
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
Tarantino, P., Prat, A., Cortés, J., Cardoso, F., & Curigliano, G. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188487 · Cited by 27
Bairi, K. E., Jarroudi, O. A., & Afqir, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.031 · Cited by 26
Lerchen, H., Stelte‐Ludwig, B., Kopitz, C., Héroult, M., Zubov, D., Willuda, J., Schlange, T., Kahnert, A., Wong, H., Izumi, R. E., et al. (2022) · Cancers · doi:10.3390/cancers14020391 · Cited by 26
Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era
Gión, M., Trapani, D., Cortés, A., Valenza, C., Lin, N., Cortés, J., & Curigliano, G. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351222 · Cited by 27
D’Angelo, A., Chapman, R., Sirico, M., Sobhani, N., Catalano, M., Mini, E., & Roviello, G. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04459-7 · Cited by 26
HER2-Low Breast Cancer: Where Are We?
Molinelli, C., Jacobs, F., Marchiò, C., Pitto, F., Cosso, M., Spinaci, S., de Azambuja, E., Schettini, F., Agostinetto, E., & Lambertini, M. (2022) · Breast Care · doi:10.1159/000527391 · Cited by 26
Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
Cano, K. S. V., Castañeda, D. H. M., Escrivá-de-Romaní, S., & Saura, C. (2022) · Cancers · doi:10.3390/cancers15010051 · Cited by 27
Self-citationFuture potential targets of antibody-drug conjugates in breast cancer
Corti, C., Bielo, L. B., Schianca, A. C., Salimbeni, B. T., Criscitiello, C., & Curigliano, G. (2023) · The Breast · doi:10.1016/j.breast.2023.03.007 · Cited by 26
Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer
Graff, S. L., Yan, F., & Abdou, Y. G. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.05.003 · Cited by 26
Improved Survival of Young Patients With Breast Cancer 40 Years and Younger at Diagnosis
Saghir, N. S. E., Khalil, L. E., Dick, J. E., Atwani, R. W., Safi, N., Charafeddine, M., Al-Masri, A., Saghir, B. N. E., Chaccour, M., Tfayli, A., et al. (2023) · JCO Global Oncology · doi:10.1200/go.22.00354 · Cited by 27
Ocular surface toxicities associated with modern anticancer therapies
Boucher, R. C., Haigh, O. L., Barreau, E., Champiat, S., Lambotte, O., Adam, C., Labétoulle, M., & Rousseau, A. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.10.002 · Cited by 26
The target atlas for antibody-drug conjugates across solid cancers
Fang, J., Guo, L., Zhang, Y., Guo, Q., Wang, M., & Wang, X. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00701-3 · Cited by 26
Antibody-Drug Conjugates: Patient and Treatment Selection
Makawita, S., & Meric‐Bernstam, F. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280775 · Cited by 27
T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives
Liu, F., Ke, J., & Song, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110407 · Cited by 26
Brain metastasis models: What should we aim to achieve better treatments?
Masmudi‐Martín, M., Zhu, L., Sánchez‐Navarro, M., Priego, N., Casanova-Acebes, M., Ruiz‐Rodado, V., Giralt, E., & Valiente, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.002 · Cited by 27
Shayeb, A. M., Kurzrock, R., Adashek, J. J., & Kato, S. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00604 · Cited by 25
Use of new and emerging cancer drugs: what the cardiologist needs to know
Fabiani, I., Chianca, M., Aimo, A., Emdin, M., Dent, S. F., Fedele, A., Cipolla, C. M., & Cardinale, D. M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae161 · Cited by 26
Li, Q., Cheng, Y., Tong, Z., Liu, Y., Wang, X., Yan, M., Chang, J., Wang, S., Du, C., Li, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48798-w · Cited by 25
Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs
Wu, D., Yang, K., He, R., Yin, R., & Shui, L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1669592 · Cited by 25
Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis
Nasrazadani, A., & Brufsky, A. (2020) · Future Oncology · doi:10.2217/fon-2019-0719 · Cited by 25
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
Tarantino, P., Morganti, S., & Curigliano, G. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00037 · Cited by 26
Bogen, J. P., Grzeschik, J., Jakobsen, J. S., Bähre, A., Hock, B. M., & Kolmar, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672262 · Cited by 25
Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
Lebert, J. M., & Lilly, E. J. (2022) · Current Oncology · doi:10.3390/curroncol29040208 · Cited by 26
Ma, Z., Zhang, Y., Zhu, M., Feng, L., Zhang, Y., & An, Z. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2121705 · Cited by 25
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
Wilcox, J. A., & Boire, A. A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00975-5 · Cited by 25
Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
Carvalho, F. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1244781 · Cited by 26
Kesireddy, M., Kothapalli, S. R., Gundepalli, S. G., & Asif, S. (2023) · Pharmaceutical Medicine · doi:10.1007/s40290-023-00505-8 · Cited by 26
Zheng, Y., Cao, W., Shao, X., Shi, Y., Cai, L., Chen, W., Liu, J., Shen, P., Chen, Y., Wang, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44140-y · Cited by 28
Michelon, I. F., Vilbert, M., Marinho, A. D., Castro, C., Dacoregio, M. I., Stecca, C., Soares, L. R., Batista, M. V., Braga, S. A., Saeed, A., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102233 · Cited by 25
Brain metastases in metastatic cancer: a review of recent advances in systemic therapies
Steindl, A., & Berghoff, A. S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1851200 · Cited by 26
Linehan, A., Fitzpatrick, O. M., & Morris, P. G. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s245024 · Cited by 25
Fetal sex determination by ultrasound scan in the second and third trimesters.
Plattner, G., Renner, W. R., Went, J., Beaudette, L., & Viau, G. (1983) · PubMed · Cited by 25
Impact of Molecular Profiling on Therapy Management in Breast Cancer
Ultimescu, F., Hudiță, A., Popa, D. E., Olincă, M., Muresean, H. A., Ceaușu, M. C., Stanciu, D. I., Ginghină, O., & Gălățeanu, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13174995 · Cited by 25
Sultana, R., Chen, S., Lim, E. H., Dent, R. A., & Chowbay, B. (2024) · BJC Reports · doi:10.1038/s44276-024-00106-1 · Cited by 24
Self-citationDacoregio, M. I., Michelon, I. F., Castro, C., de Moraes, F. C. A., de Almeida, G. R., Ravani, L. V., Vilbert, M., & Costa, R. L. B. (2024) · The Breast · doi:10.1016/j.breast.2024.103853 · Cited by 24
Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer
Kang, S., & Kim, S. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251324889 · Cited by 24
Self-citationTarantino, P., Lee, D., Foldi, J., Soulos, P. R., Gross, C. P., Grinda, T., Winer, E. P., Lin, N., Krop, I. E., Tolaney, S. M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105330 · Cited by 24
Self-citationHER2 targeting near‐infrared photoimmunotherapy for a CDDP‐resistant small‐cell lung cancer
Takahashi, K., Taki, S., Yasui, H., Nishinaga, Y., Isobe, Y., Matsui, T., Shimizu, M., Koike, C., & Sato, K. (2021) · Cancer Medicine · doi:10.1002/cam4.4381 · Cited by 25
Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer
Yang, Z., Wang, W., Wang, X., & Qin, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.741451 · Cited by 25
Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature
Ozaki, Y., Miura, S., Oki, R., Morikawa, T., & Uchino, K. (2021) · Cancers · doi:10.3390/cancers14010196 · Cited by 25
Nakajima, H., Harano, K., Nakai, T., Kusuhara, S., Nakao, T., Funasaka, C., Kondoh, C. N., Matsubara, N., Naito, Y., Hosono, A., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.01.002 · Cited by 24
Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology
Esnault, C., Schrama, D., Houben, R., Guyétant, S., Desgranges, A., Martin, C., Berthon, P., Viaud‐Massuard, M., Touzé, A., Kervarrec, T., et al. (2022) · Cancers · doi:10.3390/cancers14030778 · Cited by 24
Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Xie, J., Zou, Y., Gao, T., Xie, L., Tan, D., & Xie, X. (2022) · Cancer Control · doi:10.1177/10732748221099230 · Cited by 24
Personalized treatment approach for HER2-positive metastatic breast cancer
Pandey, P., Chaudhary, R., Tripathi, D., Lavudi, K., Dua, K., Weinfeld, M., Lavasanifar, A., & Rajinikanth, P. S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02504-4 · Cited by 26
Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer
Crowley, F., O'Cearbhaill, R. E., & Collins, D. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102225 · Cited by 24
Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials
Yu, L., Yang, R., Long, Z., Tao, Q., & Liu, B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1451230 · Cited by 23
Rugo, H. S., Tokunaga, E., Iwata, H., Petry, V., Smit, E. F., Goto, Y., Kim, D.-W., Shitara, K., Gruden, J. F., Modi, S., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.07.015 · Cited by 23
Self-citationAntibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy
Zhou, X., Han, Y., Fang, Y., Ma, P., Zhou, J., Jiang, Y., Xing, S., Tang, Q., Hou, Y., Wang, S., et al. (2025) · Med · doi:10.1016/j.medj.2025.100849 · Cited by 26
Sledge, G. W., Xiu, J., Mahtani, R. L., Sandoval-Leon, A. C., Meric‐Bernstam, F., Ribeiro, J. R., Kulkarni, N., Rampa, D. R., Lee, J., Ueno, N. T., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00868-y · Cited by 23
Development and biological assessment of MMAE-trastuzumab antibody–drug conjugates (ADCs)
Yaghoubi, S., Gharibi, T., Karimi, M. H., Nezhad, M. S., Seifalian, A. M., Tavakkol, R., Bagheri, N., Dezhkam, A., & Abdollahpour‐Alitappeh, M. (2020) · Breast Cancer · doi:10.1007/s12282-020-01153-5 · Cited by 23
Ma, K., Han, X.-X., Han, X., & Zhou, S. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.308075 · Cited by 24
Wuerstlein, R., Ellis, P., Montemurro, F., Torres, A. A., Delaloge, S., Zhang, Q., Wang, X., Wang, S., Shao, Z., Li, H., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100561 · Cited by 24
An Insight into Molecular Targets of Breast Cancer Brain Metastasis
Kaleem, M., Dalhat, M. H., Azmi, L., Asar, T. O., Ahmad, W., Alghanmi, M. S., Almostadi, A., Zughaibi, T. A., & Tabrez, S. S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911687 · Cited by 23
Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
Yang, R., Lu, G., Lv, Z., Jia, L., & Cui, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048781 · Cited by 23
Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody
Micalizzi, D. S., Che, D., Nicholson, B. T., Jon, F., Desai, N., Lang, E. R., Toner, M., Maheswaran, S., Ting, D. T., & Haber, D. A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2209563119 · Cited by 23
Yoshihara, K., Kobayashi, Y., Endo, S., Fukae, M., Hennig, S., Kastrissios, H., Kamiyama, E., Garimella, T. S., & Abutarif, M. A. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2295 · Cited by 23
Liu, Z., Zhang, H., Sun, J., Zheng, M., Cui, L., Zhang, Y., Cheng, J., Tang, Z., & Chen, X. (2023) · Advanced Materials · doi:10.1002/adma.202300377 · Cited by 23
Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)
Xu, B., & Ma, F. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.12.001 · Cited by 24
Patel, D., Mateen, R., Qaddour, N., CARRILLO, A. C., Verschraegen, C. F., Yang, Y., Li, Z., Sundi, D., Mortazavi, A., & Collier, K. A. (2024) · Cancers · doi:10.3390/cancers16020335 · Cited by 23
Bottosso, M., Mosele, F., Michiels, S., Cournède, P.-H., Doğan, S., Labaki, C., & André, F. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102247 · Cited by 23
Pedersini, R., Buffoni, M., Petrelli, F., Ghidini, A., di Mauro, P., Amoroso, V., Parati, M. C., Laini, L., Cosentini, D., Schivardi, G., et al. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.04.003 · Cited by 23
Zhang, B., Zhang, Z., Gao, J., Lu, S., Pang, R., Li, D., Huang, X., Qin, N., Liu, L., & Wang, Z. (2024) · iScience · doi:10.1016/j.isci.2024.111536 · Cited by 24
Shi, J., Liu, X., Wu, L., Jiang, Y., Zhang, Y., & Wang, Y. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241299935 · Cited by 23
Kerle, I. A., Gross, T. J., Kögler, A., Arnold, J. S., Werner, M., Eckardt, J., Möhrmann, E. E., Arlt, M., Hutter, B., Hüllein, J., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-024-00788-3 · Cited by 24
The present and future of precision oncology and tumor-agnostic therapeutic approaches
Shah, N. M., & Meric‐Bernstam, F. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf152 · Cited by 24
Xue, Q., Peng, J., Dai, W., Wu, Q., Jiao, J., Hu, Y., Sha, W., Yang, Y., Yu, W., Liu, S. M., et al. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00096c · Cited by 23
Gampenrieder, S. P., Castagnaviz, V., Rinnerthaler, G., & Greil, R. (2020) · Cancer Management and Research · doi:10.2147/cmar.s235121 · Cited by 22
Dai, M., Feng, Y. H., Chen, S. W., Masuda, N., Yau, T. C. C., Chen, S. T., Lu, Y., Yap, Y. S., Ang, P., Chu, S. C., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06313-5 · Cited by 22
Self-citationPerrotti, V., Caponio, V. C. A., Mascitti, M., Muzio, L. L., Piattelli, A., Rubini, C., Capone, E., & Sala, G. (2021) · Cancers · doi:10.3390/cancers13133126 · Cited by 22
Mao, C., Jiang, W., Huang, J., Wang, M., Yan, X., Yang, Z., Wang, D., Zhang, X., & Shen, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.817070 · Cited by 22
Verschoor, N., Deger, T., Jager, A., Sleijfer, S., Wilting, S. M., & Martens, J. W. M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102384 · Cited by 23
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Casadevall, D., Hernández‐Prat, A., García‐Alonso, S., Arpí-LLucià, O., Menéndez, S., Qin, M., Guardia, C., Morancho, B., Sánchez-Martín, F. J., Zazo, S., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0545 · Cited by 22
Thill, M., Lüftner, D., Kolberg‐Liedtke, C., Albert, U., Banys‐Paluchowski, M., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Fallenberg, E. M., et al. (2022) · Breast Care · doi:10.1159/000524789 · Cited by 23
Escrivá-de-Romaní, S., & Saura, C. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.52 · Cited by 22
Self-citationYong, W. P., Teo, F. S. W., Teo, L., Ng, M. C. H., Tan, T. J., Low, S. Y., Wong, K., Ang, P., Choo, S. P., Lee, K. H., et al. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2162383 · Cited by 22
Self-citationMetastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
Dempsey, N. G., Sandoval-Leon, A. C., & Mahtani, R. L. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01108-w · Cited by 23
Nie, C., Xu, W., Guo, Y. W., Gao, X., Lv, H., Chen, B., Wang, J., Liu, Y., Zhao, J., Wang, S., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11735-z · Cited by 24
Nicolini, A., & Ferrari, P. (2024) · Cancers · doi:10.3390/cancers16020466 · Cited by 23
Li, R., Hua, M., Li, J., Chen, W., Xu, L., Meng, H., Zhang, Z., Liu, Q., Cui, Y., & Xiang, Q. (2024) · Cancer · doi:10.1002/cncr.35349 · Cited by 23
Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads
Lerchen, H., Stelte‐Ludwig, B., Sommer, A., Berndt, S., Rebstock, A., Johannes, S., Mahlert, C., Greven, S., Dietz, L., & Jörißen, H. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00357 · Cited by 22
Central Nervous System Metastases
Nieblas‐Bedolla, E., Zuccato, J., Kluger, H. M., Zadeh, G. M., & Brastianos, P. K. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.08.004 · Cited by 22
Tan, A. C., Boggs, D. H., Lee, E. Q., Kim, M. M., Mehta, M. P., & Khasraw, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780379 · Cited by 22
Rubovszky, G., Kocsis, J., Boér, K., Chilingirova, N. P., Dank, M., Kahán, Z., Kaidarova, D., Kövér, E., Vertáková-Krakovská, B., Máhr, K., et al. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610383 · Cited by 22
HER2-Positive Breast Cancer Treatment and Resistance
Veeraraghavan, J., Angelis, C. D., Gutiérrez, C., Liao, F.-T., Sabotta, C. M., Rimawi, M. F., Osborne, C. K., & Schiff, R. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_24 · Cited by 21
Targeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches
Li, X., Xu, J., Yao, S., Zhang, N., Zhang, B., & Zhang, Z. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13691 · Cited by 22
Tumour-agnostic kinase inhibitors
Adashek, J. J., Nikanjam, M., & Kurzrock, R. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01147-y · Cited by 21
Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer
File, D. M., Curigliano, G., & Carey, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100023 · Cited by 22
Metadata
- Authors
- Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., Sohn, J., Denduluri, N., Perrin, C., Aogi, K., Tokunaga, E., Im, S.-A., Lee, K. S., Hurvitz, S. A., Cortes, J., Lee, C., Chen, S., Zhang, L., Shahidi, J., Yver, A., & Krop, I.
- Affiliations
- SHOWA Medical University (JP)
- From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 610-621
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7458671
- OpenAlex
- W2996630100
- Cited by
- 2,006
- References
- 40
- Citations by year
- 2026: 234 · 2025: 266 · 2024: 317 · 2023: 355 · 2022: 345 · 2021: 312 · 2020: 174
- FWCI
- 86.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Daiichi-Sankyo
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- trastuzumab deruxtecan, HER2-positive breast cancer, metastatic breast cancer, trastuzumab emtansine, antibody-drug conjugates, previously treated patients, objective response rate, progression-free survival, neutropenia, dose escalation, topoisomerase I inhibitor, HER2-targeted therapy, treatment efficacy and safety
- MeSH terms
- Trastuzumab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Camptothecin, Female, Humans, Middle Aged, Lung Diseases, Interstitial, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Kaplan-Meier Estimate, Intention to Treat Analysis, Consolidation Chemotherapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
